Drug Database · Clinicians

Famotidine

Brands (5) H2Bloc, Voker, Famicid-20…Show all

US brand (reference label): Pepcid; not a Philippine-registered brand.

Histamine-2 Receptor Antagonist (Histamine H2 Receptor Antagonists) US FDA class
H2-receptor antagonist PH FDA category

Rx · Prescription drug8 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID a06502d9-7903-4f37-833e-e5763d502def, version date June 1, 2024 (Pepcid · Bausch Health US LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • reduction of the risk of duodenal ulcer recurrence.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PEPCID tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:

  • active duodenal ulcer (DU).
  • active gastric ulcer (GU).
  • symptomatic nonerosive gastroesophageal reflux disease (GERD).
  • erosive esophagitis due to GERD, diagnosed by biopsy. PEPCID tablets are indicated in adults for the:
  • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
  • reduction of the risk of duodenal ulcer recurrence. PEPCID is a histamine-2 (H2) receptor antagonist indicated (1): In adult and pediatric patients 40 kg and greater for the treatment of:
  • active duodenal ulcer (DU).
  • active gastric ulcer.
  • symptomatic nonerosive gastroesophageal reflux disease (GERD).
  • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the:
  • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
  • reduction of the risk of DU recurrence.

Contraindications

4 CONTRAINDICATIONS PEPCID is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists. History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H2 receptor antagonists. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Indication Recommended Dosage (2.1)
  • Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily • See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (2.1, 2.2)
  • Administration (2.3): • Take once daily before bedtime or twice daily in the morning and before bedtime with or without food
2.1 Recommended Dosage

2.1 Recommended Dosage Table 1 shows the recommended dosage of PEPCID 20 mg and 40 mg tablets in adult and pediatric patients weighing 40 kg and greater with normal renal function. The use of PEPCID 20 mg and 40 mg tablets is not recommended in pediatric patients weighing less than 40 kg because the lowest available strength (20 mg) exceeds the recommended dose for these patients.

Use another famotidine formulation for pediatric patients weighing less than 40 kg. Table 1: Recommended Dosage and Duration of PEPCID Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function Indication Recommended Dosage Recommended Duration Active duodenal ulcer (DU) 40 mg once daily; or 20 mg twice daily Both dosages demonstrated effectiveness in clinical trials [see Clinical Studies (14)].

Up to 8 weeks In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment [see Clinical Studies (14.1)]. Longer treatment durations have not been studied in clinical trials [see Clinical Studies (14.1, 14.2, 14.3)]. Active gastric ulcer 40 mg once daily Up to 8 weeks Symptomatic nonerosive GERD 20 mg twice daily Up to 6 weeks Erosive esophagitis diagnosed by endoscopy 20 mg twice daily; or 40 mg twice daily Up to 12 weeks Pathological hypersecretory conditions In pediatric patients, the safety and effectiveness of PEPCID have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations (8.4)].

Starting dosage: 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours As clinically indicated Reduction of the risk of DU recurrence 20 mg once daily 1 year or as clinically indicated

2.2 Dosage in Renal Impairment

2.2 Dosage in Renal Impairment Dosage adjustments of PEPCID are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) [see Use in Specific Populations (8.6)]. Table 2 shows the recommended maximum dosage of PEPCID 20 mg or 40 mg tablets for patients with renal impairment, by indication.

Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet). Table 2: Maximum Dosage of PEPCID Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment Indication Recommended Maximum Dosages Creatinine clearance 30 to 60 mL/minute Creatinine clearance less than 30 mL/minute Active duodenal ulcer (DU) 20 mg once daily; or 40 mg every other day 20 mg every other day An alternate dosage regimen is 10 mg once daily.

Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. Active gastric ulcer 20 mg once daily; or 40 mg every other day 20 mg every other day Symptomatic nonerosive GERD 20 mg once daily 20 mg every other day Erosive esophagitis diagnosed by endoscopy Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see Clinical Studies (14.4)]. 20 mg once daily; or 40 mg every other day 20 mg every other day 40 mg once daily 20 mg once daily Pathological hypersecretory conditions In pediatric patients, the safety and effectiveness of PEPCID have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations (8.4)].

Avoid use Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with PEPCID for pathological hypersecretory conditions is unknown. Reduction of the risk of DU recurrence 20 mg every other day (see footnote) Recommended dosage regimen is 10 mg every other day.

Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation

2.3 Administration Instructions

2.3 Administration Instructions

  • PEPCID once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
  • PEPCID may be taken with or without food [see Clinical Pharmacology (12.3)].
  • PEPCID may be given with antacids.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.2 Dosage in Renal Impairment Dosage adjustments of PEPCID are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) [see Use in Specific Populations (8.6)]. Table 2 shows the recommended maximum dosage of PEPCID 20 mg or 40 mg tablets for patients with renal impairment, by indication.

Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet). Table 2: Maximum Dosage of PEPCID Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment Indication Recommended Maximum Dosages Creatinine clearance 30 to 60 mL/minute Creatinine clearance less than 30 mL/minute Active duodenal ulcer (DU) 20 mg once daily; or 40 mg every other day 20 mg every other day An alternate dosage regimen is 10 mg once daily.

Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. Active gastric ulcer 20 mg once daily; or 40 mg every other day 20 mg every other day Symptomatic nonerosive GERD 20 mg once daily 20 mg every other day Erosive esophagitis diagnosed by endoscopy Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see Clinical Studies (14.4)]. 20 mg once daily; or 40 mg every other day 20 mg every other day 40 mg once daily 20 mg once daily Pathological hypersecretory conditions In pediatric patients, the safety and effectiveness of PEPCID have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations (8.4)].

Avoid use Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with PEPCID for pathological hypersecretory conditions is unknown. Reduction of the risk of DU recurrence 20 mg every other day (see footnote) Recommended dosage regimen is 10 mg every other day.

Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation

8.6 Renal Impairment CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate and severe renal impairment [see Warnings and Precautions (5.1)]. The clearance of famotidine is reduced in adults with moderate and severe renal impairment compared to adults with normal renal function [see Clinical Pharmacology (12.3)].

No dosage adjustment is needed in patients with mild renal impairment (creatinine clearance greater than or equal to 60 mL/minute). Dosage reduction is recommended in adult and pediatric patients greater than or equal to 40 kg with moderate or severe renal impairment (creatinine clearance less than 60 mL/minute) [see Dosage and Administration (2.2)].

Patients with Renal Impairment In adult patients with severe renal impairment (creatinine clearance less than 30 mL/minute), the systemic exposure (AUC) of famotidine increased at least 5-fold. In patients with moderate renal impairment (creatinine clearance between 30 to 60 mL/minute), the AUC of famotidine increased at least 2-fold [see Dosage and Administration (2.2), Use in Specific Populations (8.6)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of PEPCID have been established in pediatric patients for the treatment of peptic ulcer disease (i.e., duodenal ulcer, gastric ulcer) and GERD (i.e., symptomatic nonerosive GERD, erosive esophagitis as diagnosed by endoscopy). The use of PEPCID and the recommended dosage of PEPCID in these pediatric patients is supported by evidence from adequate and well-controlled studies of PEPCID in adults and published pharmacokinetic and pharmacodynamic data in pediatric patients [see Dosage and Administration (2.1), Clinical Pharmacology (12.2, 12.3)].

In pediatric patients, the safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established. PEPCID 20 and 40 mg tablets are not recommended for use in pediatric patients weighing less than 40 kg because these tablet strengths exceed the recommended dose for these patients [see Dosage and Administration (2.1)].

For pediatric patients weighing less than 40 kg, consider another famotidine formulation (e.g., oral suspension, lower dose tablet).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 1442 PEPCID-treated patients in clinical studies, approximately 10% were 65 and older. In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving PEPCID [see Warnings and Precautions (5.1)].

Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to PEPCID may be greater in elderly patients, particularly those with impaired renal function [see Use in Specific Populations (8.6)]. In general, use the lowest effective dose of PEPCID for an elderly patient and monitor renal function [see Dosage and Administration (2.2)].

Administration

2.3 Administration Instructions • PEPCID once daily before bedtime or twice daily in the morning and before bedtime, as recommended. • PEPCID may be taken with or without food [see Clinical Pharmacology (12.3) ]. • PEPCID may be given with antacids.

US FDA label

Dosage forms

Philippines

  • Film-coated tablet: 20 mg, 40 mg
  • Lyophilized powder for injection: 20 mg
  • Powder for injection: 20 mg
  • Tablet: 20 mg

Registered products in the Philippines

8 products registered with the Food and Drug Administration (FDA) Philippines list Famotidine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products8
Philippine FDA-registered products for Famotidine
Package insert
Famicid-20Famotidine
20 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Altomed Pharmaceuticals, Inc.Importer: Diafarm Inc.
DRP-5978
Jan 29, 2030
Femostal-20Famotidine
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Pro Medica Inc.Importer: Ambica International Corporation
DRP-2864
Mar 28, 2029
H2BlocFamotidine
20 mg Film-Coated TabletFlex Foil Strip x 10's (Box of 50's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY12913
Jul 9, 2028
H2BlocFamotidine
20 mg Powder for Injection (I.M./I.V.)USP Type I Colorless, Clear Glass Vial (Box of 10's)
Rx
Myung-In Pharm. Co., Ltd.Republic of Korea
UNILAB, Inc.
DR-XY33129
Mar 22, 2032
Hista-BlocFamotidine
20 mg Lyophilized Powder for Injection (I.V.)Type I Flint Glass Vial with Rubber Stopper and Green Flip-Off Seal x 1 mL Box of 1's
Rx
Standard Chem. & Pharm. Co., LtdChina
PHIL. PHARMAWEALTH, INC.
DRP-4019
May 3, 2029
NoneFamotidine
20 mg TabletBlister Pack x 20's Box of 100's
Rx
Drugmaker's Laboratories Inc.Philippines
—
DRP-5666
May 26, 2031
VokerFamotidine
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc
DR-XY42222
Jul 18, 2028
VOKERFamotidine
40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 30's and 100's
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY32047
Aug 14, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS • 20 mg tablets: round, white to off-white film-coated tablets coded MP 973 on one side and the other side plain. • 40 mg tablets: round, white to off-white film-coated tablets coded MP 974 on one side and the other side plain. Tablets: 20 mg, 40 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Central Nervous System (CNS) Adverse Reactions: Elderly patients and patients with renal impairment at increased risk; reduce the dosage. (2.2, 5.1, 8.5, 8.6)
  • • GI Malignancy: Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy. (5.2)
5.1 Central Nervous System Adverse Reactions

5.1 Central Nervous System Adverse Reactions Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with PEPCID. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function, dosage adjustments are recommended in patients with renal impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

5.2 Concurrent Gastric Malignancy

5.2 Concurrent Gastric Malignancy In adults, symptomatic response to therapy with PEPCID does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with PEPCID.

Drug interactions

Drug interactions (US label) US FDA label
  • • Drugs Dependent on Gastric pH for Absorption: Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. See full prescribing information for a list of interacting drugs. (7.1)
  • • Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. (7.2)
7.1 Drugs Dependent

7.1 Drugs Dependent on Gastric pH for Absorption Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. Concomitant administration of PEPCID with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended.

See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine.

7.2 Tizanidine (CYP1A2 Substrate)

7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use with PEPCID. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness.

Refer to the full prescribing information for tizanidine.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Drug Interaction Studies Human Organic Anion Transporter (OAT) 1 and 3: In vitro studies indicate that famotidine is a substrate for OAT1 and OAT3.

Following coadministration of probenecid (1500 mg), an inhibitor of OAT1 and OAT3, with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC0-10h of famotidine increased from 424 to 768 ng•hr/mL and the maximum serum concentration (Cmax) increased from 73 to 113 ng/mL.

Multidrug and Toxin Extrusion Protein 1 (MATE-1): An in vitro study showed that famotidine is an inhibitor of MATE-1.

However, no clinically significant interaction with metformin, a substrate for MATE-1, was observed.

CYP1A2: Famotidine is a weak CYP1A2 inhibitor.

( 7.1) • Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible.

See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine. 7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trial Experience

6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. PEPCID was studied in 7 US and international placebo- and active-controlled trials in approximately 2500 patients [see Clinical Studies (14)].

A total of 1442 patients were treated with PEPCID, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily. The population was 17-91 years old, fairly well distributed between gender and race; however, the predominant race treated was Caucasian.

The following adverse reactions occurred in greater than or equal to 1% of PEPCID-treated patients: headache, dizziness and constipation. The following other adverse reactions were reported in less than 1% of patients in clinical trials: Body as a Whole: fever, asthenia, fatigue Cardiovascular: palpitations Gastrointestinal: elevated liver enzymes, vomiting, nausea, abdominal discomfort, anorexia, dry mouth Hematologic: thrombocytopenia Hypersensitivity: orbital edema, rash, conjunctival injection, bronchospasm Musculoskeletal: musculoskeletal pain, arthralgia Nervous System/Psychiatric: seizure, hallucinations, depression, anxiety, decreased libido, insomnia, somnolence Skin: pruritus, dry skin, flushing Special Senses: tinnitus, taste disorder Other: impotence

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of famotidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: arrhythmia, AV block, prolonged QT interval Gastrointestinal: cholestatic jaundice, hepatitis Hematologic: agranulocytosis, pancytopenia, leukopenia Hypersensitivity: anaphylaxis, angioedema, facial edema, urticaria Musculoskeletal: rhabdomyolysis, muscle cramps Nervous System/Psychiatric: confusion, agitation, paresthesia Respiratory: interstitial pneumonia Skin: toxic epidermal necrolysis/Stevens-Johnson syndrome

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data with H2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see Data).

The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Animal Data Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to PEPCID. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher.

There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Mechanism of action

12.1 Mechanism of Action Famotidine is a competitive inhibitor of histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Adults PEPCID inhibited both basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration of PEPCID, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours.

Duration of inhibition of secretion by doses of 20 mg and 40 mg was 10 to 12 hours. Single evening oral doses of 20 mg and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects.

The mean suppression was 76% and 84%, respectively, 3 to 5 hours after administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects who received the 20 mg dose, however, the antisecretory effect was dissipated within 6 to 8 hours. There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by evening doses of 20 mg and 40 mg of PEPCID to mean values of 5.0 and 6.4, respectively.

When PEPCID was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 mg or 40 mg of PEPCID was raised to about 5. PEPCID had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and exocrine pancreatic function were not affected by PEPCID. In clinical pharmacology studies, systemic effects of PEPCID in the CNS, cardiovascular, respiratory or endocrine systems were not noted.

Also, no anti-androgenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T4), and testosterone, were not altered after treatment with PEPCID. Pediatric Patients Pharmacodynamics of famotidine, assessed by gastric pH, were evaluated in 5 pediatric patients 2 to 13 years of age using the sigmoid Emax model.

These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in adults (see Table 3). Table 3: Serum Concentrations of Famotidine Associated with Gastric Acid Reduction in PEPCID-Treated Pediatric and Adult Patients Using the Sigmoid E max model, serum concentrations of famotidine associated with 50% maximum gastric acid reduction are presented as means ± SD.

EC 50 (ng/mL)a Pediatric Patients 26 ± 13 Adults Healthy adult subjects 26.5 ± 10.3 Adult patients with upper GI bleeding 18.7 ± 10.8 In a study examining the effect of famotidine on gastric pH and duration of acid suppression in pediatric patients, four pediatric patients ages 11 to 15 years of age using the oral formulation at a dose of 0.5 mg/kg, maintained a gastric pH above 5 for 13.5 ± 1.8 hours.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion Famotidine has an elimination half-life of 2.5-3.5 hours.

Renal clearance is 250 to 450 mL/minute, indicating some tubular excretion.

Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no clinical consequence. Peak famotidine plasma levels occur in 1 to 3 hours. Plasma levels after multiple dosages are similar to those after single doses.

Distribution Fifteen to 20% of famotidine in plasma is protein bound. Elimination Metabolism Famotidine undergoes minimal first-pass metabolism. Twenty-five to 30% of an oral dose was recovered in the urine as unchanged compound. The only metabolite identified in humans is the S-oxide. Excretion Famotidine has an elimination half-life of 2.5-3.5 hours.

Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/minute, indicating some tubular excretion. Specific Populations Pediatric Patients Bioavailability studies of 8 pediatric patients (11 to 15 years of age) showed a mean oral bioavailability of 0.5 compared to adult values of 0.42 to 0.49.

Oral doses of 0.5 mg per kg achieved AUCs of 580 ± 60 ng•hr/mL in pediatric patients 11 to 15 years of age, compared to 482 ± 181 ng•hr/mL in adults treated with 40 mg orally. Patients with Renal Impairment In adult patients with severe renal impairment (creatinine clearance less than 30 mL/minute), the systemic exposure (AUC) of famotidine increased at least 5-fold.

In patients with moderate renal impairment (creatinine clearance between 30 to 60 mL/minute), the AUC of famotidine increased at least 2-fold [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Drug Interaction Studies Human Organic Anion Transporter (OAT) 1 and 3: In vitro studies indicate that famotidine is a substrate for OAT1 and OAT3.

Following coadministration of probenecid (1500 mg), an inhibitor of OAT1 and OAT3, with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC0-10h of famotidine increased from 424 to 768 ng•hr/mL and the maximum serum concentration (Cmax) increased from 73 to 113 ng/mL. Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased.

The clinical relevance of this interaction is unknown. Multidrug and Toxin Extrusion Protein 1 (MATE-1): An in vitro study showed that famotidine is an inhibitor of MATE-1. However, no clinically significant interaction with metformin, a substrate for MATE-1, was observed. CYP1A2: Famotidine is a weak CYP1A2 inhibitor.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Famotidine 10 mg/mL, 2 mL Ampule₱129.49–₱212.40Reference ₱129.49per ampuleDPRI procurement range
Famotidine 10 mg/mL, 2 mL Vial₱88.33–₱289.33Reference ₱88.33per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Famotidine
PNF listingOral: 20 mg tablet
PNF listingInj.: 20 mg powder/lyophilized powder for injection, ampule/vial
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Pepcid · Bausch Health US LLC [US FDA-approved label, version 8, June 1, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a06502d9-7903-4f37-833e-e5763d502def
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .